Stem Cell Therapy Company Amniotics Raises SEK 60 Million before Deduction of Transaction Costs, in First North IPO to Advance Lead Candidate PulmoStem^™ Into Clinic

Amniotics AB has raised SEK60 million through its recent listing on Nasdaq. The funds will now be deployed to advance the company’s preclinical portfolio of cell therapy candidates based on MSC from amniotic fluid. Lead candidate PulmoStem™, a first-in-class treatment for pulmonary disease is scheduled to enter the clinic.